HighLife SAS, a medtech company focused on the development of a unique Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from moderate to severe mitral regurgitation (MR), announced …
HighLife SAS, a medtech company focused on the development of a unique Trans-Septal Mitral Valve Replacement (“TSMVR”) system to treat patients suffering from mitral regurgitation, announced today that several presentations will be …
First 3 activated clinical centers in France enroll patients HighLife SAS announced today the start of its European clinical study with the enrollment of the first 3 patients at major …
HighLife SAS announced today the successful treatment of 5 consecutive patients in its early feasibility clinical phase. The first three cases were carried out in Kiev (Ukraine) in the adult …
